Advanced Generation Folate Therapy-EnLyte-Patented To Treat High Homocysteine, a Condition Associated with PTSD, Announces JayMac Pharmaceuticals, LLC
| PR Web |
(PRWEB)
PTSD (Post Traumatic Stress Disorder) among military men and women is prevalent, with over 10,000 new cases diagnosed each year, some requiring hospitalization. A link between PTSD and high homocysteine – an amino acid – has been validated in many studies. Many things can contribute to high homocysteine, including extreme stress, as would be expected in PTSD, and genetic issues such as the MTHFR polymorphism. A critical combination of B vitamins and co-factors is needed to keep homocysteine in a healthy range, and when elevated, it can lead to cardiovascular disease, stroke, dementia, and a host of other health problems.
One study published by Levine, et al. in Depression and Anxiety found "the duration of PTSD was found to predict serum homocysteine levels. Our results suggest that elevated levels of homocysteine in male patients with PTSD may be related to pathophysiological aspects associated with the chronicity of this disorder." Another study published by Jendricko, et al. in Progress in NeuroPsychopharmacology & Biological Psychiatry found homocysteine levels significantly higher in men with PTSD than in those without.
Antidepresssants and cognitive therapy are the most common ways to treat this disorder. Adding a homocysteine-lowering agent to this regimen would help improve symptoms and overall health long term. There is only one patented drug containing all of the necessary ingredients to lower homocysteine – EnLyte with Delta Folate. This is a new, natural, advanced generation folate therapy containing all natural, unique, and reduced folates and co-factors, as well as other minerals for overall brain health. It may be used alone or added to an SSRI/SNRI. With both the depression and hyperhomocysteinemia indications, this new drug has huge potential to assist in the military arena:
• Treat PTSD Symptoms and Lower Homocysteine: It would reduce homocysteine levels and would improve clinical drug outcomes when added to an SSRI/SNRI
• Provide a safe, effective, and natural option to treat depression without side effects
• Pregnancy category A
•
• DMLSS coverage
•
To learn more, visit http://www.EnlyteRx.Com.
Read the full story at http://www.prweb.com/releases/2014/07/prweb12044149.htm
| Copyright: | (c) 2014 PRWEB.COM Newswire |
| Wordcount: | 380 |


Doing right by ‘Lady Justice’: Restoration planned for statue, dome
Advisor News
- Poor money habits are a dealbreaker in a new relationship
- DC plan sponsors see opportunity in alternatives
- The American Dream: Redefined as financial stability
- Partial annuitization: How advisors can help clients balance income, growth
- Guide women along the walk through widowhood
More Advisor NewsAnnuity News
- Globe Life Inc. (NYSE: GL) Records 52-Week High Thursday Morning
- AM Best Managing Director Joins ‘Target Topics’ Podcast to Discuss State of Delegated Underwriting Authority Enterprises Market
- KBRA Assigns Rating to TruSpire Retirement Insurance Company
- Partial annuitization: How advisors can help clients balance income, growth
- Guide women along the walk through widowhood
More Annuity NewsHealth/Employee Benefits News
- Health benefit premiums for NJ school workers expected to rise by 34%
- Atrium’s WakeMed acquisition faces new hurdle after State Health Plan decision
- Fewer members, more profit: UnitedHealth shares surge on Q2 earnings beat
- ARE SURVIVAL RATES FOR ADULTS WITH CONGENITAL HEART DISEASE LINKED TO SPECIALIZED CARDIAC CARE ACCESS?
- THIRTY-TWO YEARS, ZERO RESULTS: NRSC CHARGES SHERROD BROWN SOLD OUT TO BIG INSURANCE
More Health/Employee Benefits NewsLife Insurance News
- Globe Life Inc. (NYSE: GL) Records 52-Week High Thursday Morning
- AM Best Upgrades Credit Ratings of Sagicor Financial Company Ltd. and Most of Its Subsidiaries
- Trust, technology and the future of claims
- New York Life Launches an Indemnity Benefit for its Asset Flex Long-Term Care Insurance Solution
- AM Best Affirms Credit Ratings of DB Insurance Co., Ltd.
More Life Insurance News